United States (USA) Biobanking Market Overview, 2029

In the US, biobanking and stem cell banking are symbolic of modern medicine, biological sample repositories for study and development of new medication, and individualised healthcare. These biological material banks collect, manage, and store many different kinds of biological resources, such as stem cells extracted from bone marrow, umbilical cord blood, and other tissues. Private stem cell banks provides what families and individuals need to protect stem cells for potential use in medical treatments in the future. This cooperative ecosystem of stem cell research and biobanking propels innovation in areas such as regenerative medicine, cancer medicines, and hereditary illnesses. Tight regulatory criteria ensure patient confidentiality, moral application, and superior quality samples, thereby boosting public confidence in these priceless resources. To put it simply, biobanking and stem cell banking are the backbones of biomedical progress in the United States, driving major advances and improvements in healthcare. In United States biobanking and stem cell banking would undergo revolutionary growth and development in the near future. These industries have a lot of promise to change biomedical research and therapy given the advancement of technology and our expanding biological understanding. The integration of modern technologies like high-throughput sequencing, machine learning, and artificial intelligence with biobanking has the potential to speed up the identification of illness biomarkers, therapeutic targets, and personalised therapies. The expansion of bio banks to include more diverse populations and comprehensive datasets will enable researchers to address health disparities and develop interventions tailored to individual and community needs. Innovative cell sources, such induced pluripotent stem cells, are creating new avenues for individualised treatment plans and disease models. Looking ahead, the combination of biobanking with stem cell banking presents synergistic potential for interdisciplinary collaboration and innovation.. Through the integration of stem cell technology with genetic, clinical, and cellular data from extensive biobanks, scientists can enhance their understanding of disease causes, expedite drug discovery, and provide more potent treatments. Furthermore, the incorporation of stem cells obtained from patients into precision medicine endeavours possesses the capability to transform healthcare by offering customised therapies that are determined by an individual's genetic composition and illness characteristics.


According to the research report "USA Biobanking/ Stempcell Banking Market Overview, 2029," published by Bonafide Research, the USA Biobanking/ Stempcell Banking market was valued at more than USD 18.5 Billion in 2029. There are three main components make up the infrastructure of biobanking in the United States consumables, equipment, and Laboratory Information Systems (LIS).The foundation of every bio bank facility is its equipment, which comprises a range of devices for sample processing and analysis as well as ultra-low temperature freezers for the long-term preservation of biological materials. These tools allow biologists to utilise biological specimens for a range of analyses and investigations while maintaining their integrity and preservation. Consumables, which include a wide range of products like vials, tubes, labels, and chemicals required for sample collection, storage, and analysis, are also crucial to the biobanking process. The use of premium consumables is essential to preventing contamination and maintaining sample quality, which is necessary for reproducible and accurate study results. Laboratory Information Systems (LIS) are used in biobanks to manage, track, and combine data related to sample acquisition, storage, and analysis.

With significant expansion the biobanking services has and changed in several areas of United States . The growing need for high-quality biological specimens for biomedical research, drug development, and personalized medicine initiatives has led to a major expansion of biobanking and repository services. Bio banks have expanded their services to include a variety of sample types, such as tissues, blood, DNA, RNA, and cell lines, as well as complete data management systems to support integrated research initiatives, in response to the growing complexity and multidisciplinary nature of research endeavor’s. Lab processing services have evolved greatly with the introduction of automation and high-throughput technology to boost efficiency and throughput while streamlining sample processing procedures. As a result, biobanks have been able to grow and meet the growing need for processed samples while maintaining stringent quality control protocols to minimise variation and safeguard sample integrity. Cold chain logistics services have developed into increasingly complicated offerings that ensure the stability and integrity of samples during storage and transit. These services make use of state-of-the-art temperature monitoring systems, real-time tracking tools, and customised packaging solutions. The globalisation of clinical trials and research collaborations has led cold chain logistics companies to expand their services to include sample transportation across borders and strict regulatory compliance. Services encompass a broad range of goods and services, such as data management and informatics systems, ethics and regulatory advice, community engagement and consent facilitation, and specialised sample collection and processing services for specific research needs. As the field of biobanking continues to evolve, these auxiliary services are essential to the growth and sustainability of biobanking operations as well as to the collaboration and inventiveness of the biomedical research community.


Both physical and virtual biobanks are rising in popular in the US, catering to different needs and interests of the scientific community. The number of physical biobanks—physical repositories of biological samples under tight control—has increased dramatically during the past few years. These physical locations are essential for the storage and management of an enormous variety of biological specimens, from tissue samples to bio fluids, enabling numerous research projects in a variety of fields. Recent developments in biobanking industry such as technological developments in automation, quality control, and storage have propelled the expansion of physical bio banks, allowing these establishments to fulfill the growing demand for high-quality biological samples while guaranteeing sample integrity and traceability. Virtual bio banks provide a fresh and creative take on biobanking by enabling the exchange of biological and clinical data between institutions and researchers through the use of digital platforms and data-sharing networks. Faster research collaborations, improved access to a variety of datasets, and the capacity to collect data for extensive studies from several sources are just a few of its additional benefits. Virtual biobanks are becoming more and more common, which indicates that data-driven research methods are becoming more and more important, and that cooperation and data sharing are important for increasing precision medicine and biomedical research..


Significant growth has been seen in a number of sectors within the ever-changing landscape of biobanking applications in the United States, including drug discovery and clinical research, medicines development, clinical diagnostics, and other developing fields. Growing need for high-quality biological samples to support preclinical and clinical investigations has led to significant expansion in drug discovery and clinical research. Bio banks are essential for giving researchers access to a variety of well-characterized samples, which helps with the search and creation of new treatments for a variety of diseases. The need for annotated bio specimens suited to certain patient populations is increasing as the pharmaceutical industry adopts personalized medicine techniques and targeted medicines, which is propelling the development of biobanking infrastructure and services. The field of therapeutics has grown significantly as well, and bio banks are now essential sources of biological materials for gene treatments, cell therapies, and regenerative medicine techniques. Bio banks facilitate the expeditious translation of potential therapies from bench to bedside by giving researchers and biopharmaceutical firm’s access to clinically relevant samples for biomarker identification, target validation, and safety assessment. The importance of biobanking in promoting innovative methods to illness management and treatment is highlighted by the growing emphasis on precision medicine and personalised treatments. Clinical diagnostics is another area where biobanking is growing, driven by advancements in genome sequencing, molecular diagnostics, and personalised healthcare programmes. Bio banks are crucial sources of high-quality samples for the development, validation, and clinical testing of diagnostic assays in order to facilitate the identification of disease. With the growing demand for targeted diagnostic tools and targeted medications, biobanks are poised to play an increasingly important role in the development of clinical diagnostics and improving patient outcomes.



Considered in this report
• Historic year: 2018
• Base year: 2023
• Estimated year: 2024
• Forecast year: 2029

Aspects covered in this report
• Biobanking market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Equipment
• Consumables
• Laboratory Information Systems

By Service Type
• Biobanking and Repository
• Validation/Qualification
• Lab Processing
• Cold Chain Logistic
• Others

By Biospecimen Type
• Human Tissues
• Stem Cells
• Organs
• Others

By Biobank
• Physical Biobanks
• Virtual Biobanks

By Application
• Drug Discovery and Clinical Research
• Therapeutics
• Clinical Diagnostics
• Others

By Type of Biobank
• Population-based Biobanks
• Disease-oriented Biobanks

By Ownership
• National/regional agency
• Non-Profit Organization
• Universities
• Private Organization

By Storage
• Manual Storage
• Automated Storage

The approach of the report:
This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the Biobanking industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.